Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
Quercetin inhibits the growth and migration of HBV-associated hepatocellular carcinoma by targeting EGFR, leading to downstream suppression of the PI3K/AKT/GSK3B pathway and reversal of EMT.
Background: Quercetin, a flavonoid present in many plants, shows therapeutic potential against hepatocellular carcinoma (HCC). Its specific mechanism in HBV-associated HCC (HBV-HCC) is unclear. Methods: Integrated in vitro and in vivo models were employed, assessing quercetin effects on HCC cell viability, proliferation, clonogenicity, and migration via CCK-8, EdU, colony formation, and scratch assays. Network pharmacology and molecular docking identified potential quercetin targets. Lentiviral transfection constructed HCC lines overexpressing HBx and EGFR; signaling pathways were confirmed via Western blot. A xenograft mouse model evaluated therapeutic efficacy, including combination with EGFR inhibitor osimertinib. Results: Target network analysis identified 29 therapeutic targets, with EGFR as the principal target. Docking showed EGFR and GSK3β binding affinity. In vitro studies revealed quercetin dose‑dependently suppresses EGFR, attenuates PI3K/AKT/GSK3β signaling, and reverses EMT, reducing growth and migration of HBV-HCC cells. In vivo studies with EGFR inhibitors further validated quercetin’s anti‑tumor effects through EGFR targeting and EMT suppression. Conclusion: Quercetin demonstrates therapeutic effectiveness in inhibiting HBV-HCC by targeting EGFR, thereby suppressing PI3K/AKT/GSK3β signaling, reversing EMT, and impeding progression. This provides a novel basis for targeted HBV‑HCC therapy with quercetin.
This research validates the therapeutic effectiveness of quercetin in inhibiting HBV‑HCC and elucidates the molecular mechanisms responsible for its action.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort
- Hepatocellular Carcinoma: A Comprehensive Review